Literature DB >> 33971784

The furosemide stress test: current use and future potential.

Blaithin A McMahon1, Lakhmir S Chawla2.   

Abstract

Loop diuretics are among the most widely used drugs worldwide and are commonly employed in the management of complications associated with acute kidney injury (AKI), namely volume overload and electrolyte management. The use of loop diuretics in critically ill patients with AKI is paramount to preventing or treating pulmonary edema. The naturetic response to a loop diuretic is based on its unique renal pharmacology. Our review article summarizes the pharmacology of furosemide in the intact nephron and discusses how this response might be altered by the presence of AKI. We discuss the increasing body of literature on the latest clinical utility of furosemide namely, it's challenge test, known as the furosemide stress test which has highlighted a new and novel role for furosemide over the past number of years. This test assists with the identification of AKI subjects at higher risk of AKI progression and the need for renal replacement therapy. The stress test can also predict cessation of continuous renal replacement therapy in patients with established AKI. On the basis of the evidence presented in this review, we propose future potential studies of furosemide in AKI.

Entities:  

Keywords:  Furosemide; acute kidney injury; renal replacement therapy; risk assessment; stress test

Year:  2021        PMID: 33971784     DOI: 10.1080/0886022X.2021.1906701

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  2 in total

1.  New diagnostics for AKI in critically ill patients: what to expect in the future.

Authors:  Greet De Vlieger; Lui Forni; Antoine Schneider
Journal:  Intensive Care Med       Date:  2022-08-16       Impact factor: 41.787

Review 2.  Rhabdomyolysis-Induced AKI (RIAKI) Including the Role of COVID-19.

Authors:  Ewelina Młynarska; Julia Krzemińska; Magdalena Wronka; Beata Franczyk; Jacek Rysz
Journal:  Int J Mol Sci       Date:  2022-07-26       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.